Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome

Pediatric Blood and Cancer

Volumn 62, Issue 1, 2015, Pages 148-152

  Goto, Hiroaki ^a   Kaneko, Takashi ^b   Shioda, Yoko ^c   Kajiwara, Michiko ^d   Sakashita, Kazuo ^e   Kitoh, Toshiyuki ^f   Hayakawa, Akira ^g   Miki, Mizuka ^h   Kato, Keisuke ⁱ   Ogawa, Atsushi ^j   Hashii, Yoshiko ^k   Inukai, Takeshi ^l   Kato, Chiaki ^m   Sakamaki, Hisashi ⁿ   Yabe, Hiromasa ^o   Suzuki, Ritsuro ^p   Kato, Koji ^q  

^a KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^b TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

^e SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Shiga Medical Center for Children   (Japan)

^g KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

ⁱ Ibaraki Children's Hospital   (Japan)

^j NIIGATA CANCER CENTER HOSPITAL   (Japan)

^k OSAKA UNIVERSITY HOSPITAL   (Japan)

^l UNIVERSITY OF YAMANASHI   (Japan)

^m Meitetsu Hospital   (Japan)

ⁿ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^o TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

more..

Author keywords

Acute lymphoblastic leukemia; Down syndrome; GVHD; Relapse; Transplantation

Indexed keywords

BUSULFAN; FLUDARABINE; MELPHALAN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGRAFT; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER REGISTRY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DOWN SYNDROME; ENGRAFTMENT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; MALE; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNRELATED DONORS; WHOLE BODY RADIATION; ADOLESCENT; ALLOTRANSPLANTATION; COMPLICATION; FOLLOW UP; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JAPAN; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; JAPAN; MALE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84922803297     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25245     Document Type: Article

References (31)

1. Bruwier A, Chantrain CF. Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr 2012; 171:1301-1307.
2. Izraeli S, Vora A, Zwaan CM, et al. How I treat ALL in Down's syndrome: Pathobiology and management. Blood 2014; 123:35-40.
3. Sorrell AD, Alonzo TA, Hilden JM, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971 a report from the Children's Oncology Group. Cancer 2012; 118:4806-4814.
4. Taga T, Shimomura Y, Horikoshi Y, et al. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatr Blood Cancer 2011; 57:36-40.
5. Lundin C, Forestier E, Klarskov Andersen M, et al. Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries. J Hematol Oncol 2014; 7:32.
6. Patrick K, Wade R, Goulden N, et al. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. Br J Haematol 2014; 165:552-555.
7. Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood 2014; 123:70-77.
8. Buitenkamp TD, Pieters R, Gallimore NE, et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: Role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012; 26:2204-2211.
9. Loudin MG, Wang J, Leung HC, et al. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 2011; 25:1555-1563.
10. Rabin KR, Smith J, Kozinetz CA. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58:633-635.
11. Christensen MS, Heyman M, Möttönen M, et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 2005; 131:50-58.
12. Bohnstedt C, Levinsen M, Rosthøj S, et al. Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. Leukemia 2013; 27:866-870.
13. Goto H, Inukai T, Inoue H, et al. Acute lymphoblastic leukemia and Down syndrome: The collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group. Int J Hematol 2011; 93:192-198.
14. Rubin CM, Mick R, Johnson FL. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: Toxicity and outcome. Bone Marrow Transplant 1996; 18:533-540.
15. Rubin CM, O'Leary M, Koch PA, et al. Bone marrow transplantation for children with acute leukemia and Down syndrome. Pediatrics 1986; 78:688-691.
16. Meissner B, Borkhardt A, Dilloo D, et al. Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone Marrow Transplant 2007; 40:945-949.
17. Hitzler JK, He W, Doyle J, et al. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2014; 61:1126-1128.
18. Buitenkamp TD, Mathôt RA, de Haas V, et al. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 2010; 95:1106-1113.
19. Hitzler JK, He W, Doyle J, et al. Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biol Blood Marrow Transplant 2013; 19:893-897.
20. Muramatsu H, Sakaguchi H, Taga T, et al. Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. Pediatr Blood Cancer 2014; 61:925-927.
21. Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. Eur J Pediatr 2010; 69:1445-1452.
22. Bruijn M, van der Aa LB, van Rijn RR, et al. High incidence of acute lung injury in children with Down syndrome. Intensive Care Med 2007; 33:2179-2182.
23. Eom KS, Shin SH, Yoon JH, et al., Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol 2013; 88: 634-641.
24. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116:4439-4443.
25. Paczesny S1, Hanauer D, Sun Y, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010; 45:1-11.
26. Bloemers BL, Bont L, de Weger RA, et al. Decreased thymic output accounts for decreased naive T cell numbers in children with Down syndrome. J Immunol 2011; 186:4500-4507.
27. Clave E, Rocha V, Talvensaari K, et al. Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation. Blood 2005; 105:2608-2613.
28. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73:1729-1734.
29. Zikos P, Van Lint MT, Frassoni F, et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: A randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91:3503-3508.
30. Hudspeth MP, Heath TS, Chiuzan C, et al. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Bone Marrow Transplant 2013; 48:46-49.
31. Sugita J, Matsushita T, Kashiwazaki H, et al. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant 2012; 47:258-264.